retatrutide phase 3 2025 triple agonist glp-1 gip glucagon A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide Delivers 22.6% Weight Loss

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W

Our manufacturing and handling protocols prioritize purity, stability, and consistency

They help heal wounds, build muscles, and fight infections

Other contraindications and caution flags include Wilsons disease or another copper-handling disorder, pregnancy, recent surgery, and WADA-tested competition

Given how quickly this status has changed since 2023, readers should treat ipamorelin's compounding legality as unsettled rather than fixed, and verify current status directly with the FDA or a licensed pharmacist before assuming a lawful compounding pathway exists